Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 15/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.48 |
| ▸ | USP2 | O75604 | 14/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 12/20 | 0.48 |
| ▸ | MEN1 | O00255 | 11/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.48 |
| ▸ | GLA | P06280 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581677 | 0.88 | MKNK1 (0.54) | KMT2AHTR2A | |
| SCHEMBL4580382 | 0.81 | ALDH1A1 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C19USP2 | |
| SCHEMBL4580579 | 0.80 | ACHE (0.47) | CLK4ACHE | |
| SCHEMBL4581947 | 0.79 | OGA (0.43) | KDM4EMAPTHTR2A | |
| SCHEMBL4581037 | 0.79 | MKNK1 (0.48) | HTR2A | |
| SCHEMBL4580354 | 0.79 | OGA (0.55) | HTR2A | |
| SCHEMBL4580238 | 0.77 | HRH4 (0.48) | ALDH1A1HTR2A | |
| SCHEMBL4581886 | 0.77 | OGA (0.48) | HTR2A | |
| SCHEMBL4580672 | 0.76 | OGA (0.48) | HTR2A | |
| SCHEMBL4581286 | 0.76 | IDH1 (0.41) | ALDH1A1HIF1AKDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | claimed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | CYP1A2 1524/4885CYP3A4 1806/4885CYP2D6 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.